FDA Issues Alert for Medtronic Esophageal Monitoring Devices
The agency warns of potential high-risk issues with Bravo CF delivery systems following reports of 184 serious injuries.
The agency warns of potential high-risk issues with Bravo CF delivery systems following reports of 184 serious injuries.
The agency warns of a high-risk issue where needle components may lock during insertion, potentially delaying critical care.
The newly cleared contrast-enhanced mammography and biopsy capabilities aim to help radiologists characterize suspicious findings and perform targeted biopsies more efficiently.
The FDA-cleared update automates measurement tasks and provides clinical decision support to improve imaging workflow.
A manufacturing error may lead to undetected oxygen leaks, posing risks of reduced oxygen delivery and potential fire hazards.
Admetsys announced that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
The U.S. FDA has proposed banning electrical stimulation devices for self-injurious or aggressive behavior due to significant risks, marking the second attempt at prohibition, with implications including potential treatment transitions for users and a thorough review of updated evidence and expert opinions.